Chronic kidney disease (CKD) is usually associated with cardiac apoptosis and/or cardiac hypertrophy. We hypothesized that exercise can reduce the CKD-induced cardiac damage.
Methods and results
The doxorubicin-induced CKD (DRCKD) model was used in rats to compare two exercise models: 60-min running and 60-min swimming. Results indicated that in healthy normal groups, the signals cardiotrophin-1 (CT-1), interleukin 6 (IL-6), leukaemia inhibitory factor receptor (LIFR), and gp130 were upregulated and janus kinase (JAK) and signal transducer and activation of transcription (STAT) were downregulated by both exercises. In contrast, all signals were highly upregulated in CKD. After exercise training, all signals (CT-1, IL-6, LIFR, gp130, and STAT) were downregulated, with JAK being only slightly upregulated in the running group but not in the swimming group. The myocyte death pathway (CT-1/IL-6 → LIFR/gp130 → PI3K → Akt → Bad) was excluded due to no change found for Bad. Nitric oxide (NO; normal, 15.63 ± 0.86 µmol/l) was significantly suppressed in CKD rats (2.95 ± 0.32 µmol/l), and both running and swimming training highly upregulated the NO level to 30.33 ± 1.03 µmol/l and 27.82 ± 2.47 µmol/l in normal subjects and 24.0 ± 3.2 µmol/l and 22.69 ± 3.79 µmol/l in the DRCKD rats, respectively. The endothelial progenic cells CD34 were significantly suppressed in DRCKD rats, which were not rescued significantly by exercise. In contrast, the CD 34 cells were only slightly suppressed in the healthy subjects by exercise.
Conclusion
Both exercise regimens were beneficial by rescuing cardiac function in CKD victims. Its action mechanism was by way of inhibiting myocyte death and rescuing cardiac hypertrophy.
ManjunathGTighiouartHIbrahimH. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol2003; 41: 47–55.
2.
NapoliCCasamassimiACrudeleV. Kidney and heart interactions during cardiorenal syndrome: a molecular and clinical pathogenic framework. Future Cardiol2011; 7: 485–497.
3.
ParfreyPS. Cardiac disease in dialysis patients: diagnosis, burden of disease prognosis, risk factors and management. Nephrol Dial Transplant2000; 15: 58–68.
4.
CulletonBFLarsonMGWilsonPW. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int1999; 56: 2214–2219.
5.
Miranda SdePMacedoRNSilva JúniorGB. Cardio-renal syndrome: pathophysiology and treatment. Rev Assoc Med Bras2009; 55: 89–94.
6.
LevinAThompsonCREthierJ. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis1999; 34: 125–134.
7.
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis2002; 39: S1–S266.
EngelDPeshockRArmstongRC. Cardiac myocyte apoptosis provokes adverse cardiac remodeling in transgenic mice with targeted TNF overexpression. Am J Physiol Heart Circ Physiol2004; 287: H1303–H1311.
16.
HaudekSBTaffetGESchneiderMD. TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways. J Clin Invest2007; 117: 2692–2701.
17.
KaurKSharmaAKDhingraS. Interplay of TNF-alpha and IL-10 in regulating oxidative stress in isolated adult cardiac myocytes. J Mol Cell Cardiol2006; 41: 1023–1030.
18.
KimYSMorganMJChoksiS. TNF-induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death. Mol Cell2007; 26: 675–687.
19.
KaurJDhaunsiGTurnerR. Interleukin-1 and nitric oxide increase NADPH oxidase activity in human coronary artery smooth muscle cells. Med Princ Pract2004; 13: 26–29.
20.
MullensWAbrahamsZFrancisGS. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol2009; 53: 589–596.
21.
DammanKVoorsAAHillegeHL. CIBIS-2 Investigators and Committees. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Heart Fail2010; 12: 974–982.
22.
OnatDJelicSSchmidtAM. Vascular endothelial sampling and analysis of gene transcripts: a new quantitative approach to monitor vascular inflammation. J Appl Physiol2007; 103: 1873–1878.
23.
ColomboPCBanchsJECelajS. Endothelial cell activation in patients with decompensated heart failure. Circulation2005; 111: 58–62.
24.
JougasakiM. Cardiotrophin-1 in cardiovascular regulation. Adv Clin Chem2010; 52: 41–76.
25.
CalabròPLimongelliGRieglewrLV. Novel insights into the role of cardiotrophin-1 in cardiovascular diseases. J Mol Cell Cardiol2009; 46: 142–148.
26.
PembertonCJRaudseppSDYandleTG. Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch. Cardiovasc Res2005; 68: 109–117.
27.
LopezBGonzalezALasarteJJ. Is plasma cardiotrophin-1 a marker of hypertensive heart disease?J Hypertens2005; 23: 625–632.
28.
CottoneSNardiEMulèG. Association between biomarkers of inflammation and left ventricular hypertrophy in moderate chronic kidney disease. Clin Nephrol2007; 67: 209–216.
29.
TalwarSSquireIBDowniePF. Elevated circulating cardiotrophin-1 in heart failure: relationship with parameters of left ventricular systolic dysfunction. Clin Sci (Lond)2000; 99: 83–88.
30.
JougasakiM. Cardiotrophin-1 in cardiovascular regulation. Adv Clin Chem2010; 52: 41–76.
31.
LeeVWHarrisDC. Adriamycin nephropathy: a model of focal segmental glomerulosclerosis. Nephrology (Carlton)2011; 16: 30–38.
MettlerFPYoungDMWardJM. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res1977; 37: 2705–2713.
34.
SzymanskiMKde BoerRANavisGJ. Animal models of cardiorenal syndrome: a review. Heart Fail Rev2012; 17: 411–420.
35.
Noiri E, Nagano N, Negishi K, Doi K, Miyata S, Abe M, et al. Efficacy of darbepoetin in doxorubicin-induced cardiorenal injury in rats. Nephron Exp Nephrol 2006; 104: e6–e14.
36.
Canadian Institute for Health. Information; dialysis and renal transplantation2001; Vol. 1. Ottawa, Canada: Canadian Organ Replacement Register.
37.
SarnakMJLeveyAS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis2000; 35: S117–S131.
38.
PainterP. Exercise in chronic disease: physiological research needed. Exerc Sport Sci Rev2008; 36: 83–90.
39.
Bloomfield SA and Coyle EF. Bed rest, detraining, and retention of training-induced adaptations: a review. In: American Collage of Sports Medicine (eds) Resource manual for guidelines for exercise testing and prescription. 2nd edn. Philadelphia: Lea and Febiger, 1993. pp. 115–128.
40.
MillerTDBaladyGJFletcherGF. Exercise and its role in the prevention and rehabilitation of cardiovascular disease. Ann Behav Med1997; 19: 220–229.
41.
StevensLACoreshJGreeneT. Assessing kidney function – measured and estimated glomerular filtration rate. N Engl J Med2006; 354: 2473–2483.
42.
National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. New York: NKF. Available at: www.kidney.org/professionals/kdoqi/guidelines_ckd/toc.htm (2002, consulted August 2010).
43.
LiangYLiYJ. Expression of JAKs/STATs pathway molecules in rat model of rapid focal segmental glomerulosclerosis. Pediatr Nephrol2009; 24: 1667–1671.
44.
AdamsGRVaziriND. Skeletal muscle dysfunction in chronic renal failure: effects of exercise. Am J Physiol Renal Physiol2006; 290: F753–F761.
45.
HirschbergRKoppleJD. Evidence that insulin-like growth factor I increases renal plasma flow and glomerular filtration rate in fasted rats. J Clin Invest1989; 83: 326–330.
46.
HusainK. Physical conditioning modulates rat cardiac vascular endothelial growth factor gene expression in nitric oxide-deficient hypertension. Biochem Biophys Res Commun2004; 320: 1169–1174.
47.
BarouchLACappolaTPHarrisonRW. Combined loss of neuronal and endothelial nitric oxide synthase causes premature mortality and age-related hypertrophic cardiac remodeling in mice. J Mol Cell Cardiol2003; 35: 637–644.
MuradF. The role of nitric oxide in modulating guanylyl cyclase. Neurotransmission1994; 10: 1–4.
50.
d'IschiaMPalumboABuzzoF. Interactions of nitric oxide with lipid peroxidation products under aerobic conditions: inhibitory effects on the formation of malondialdehyde and related thiobarbituric acid-reactive substances. Nitric Oxide2000; 4: 4–14.
51.
PengCCChenKCHsiehCL. Swimming exercise prevents fibrogenesis in chronic kidney disease by inhibiting the myofibroblast transdifferentiation. PLoS One2012; 7(6): e37388–e37388.
52.
PennicaDKingKLShawKJ. Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci USA1995; 92: 1142–1146.
53.
StephanouABrarBHeadsR. Cardiotrophin-1 induces heat shock protein accumulation in cultured cardiac cells and protects them from stressful stimuli. J Mol Cell Cardiol1998; 30: 849–855.
54.
WollertKCTagaTSaitoM. Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series VIA gp130/leukemia inhibitory factor receptor-dependent pathways. J Biol Chem1996; 271: 9535–9545.
55.
FreedDHChiltonLLiY. Role of myosin light chain kinase in cardiotrophin-1-induced cardiac myofibroblast cell migration. Am J Physiol Heart Circ Physiol2011; 301: H514–H522.
56.
ZolkOEngmannSMünzelF. Chronic cardiotrophin-1 stimulation impairs contractile function in reconstituted heart tissue. Am J Physiol Endocrinol Metab2005; 288: E1214–E1221.
57.
TsutamotoTAsaiSTanakaT. Plasma level of cardiotrophin-1 as a prognostic predictor in patients with chronic heart failure. Eur J Heart Fail2007; 9: 1032–1037.
58.
AdamsGRZhanCDHaddadF. Voluntary exercise during chronic renal failure in rats. Med Sci Sports Exerc2005; 37: 557–562.
59.
FreedDHCunningtonRHDangerfieldAL. Emerging evidence for the role of cardiotrophin-1 in cardiac repair in the infracted heart. Cardiovasc Res2005; 65: 782–792.
60.
MatsuiHFujioYKunisadaK. Leukemia inhibitory factor induces a hypertrophic response mediated by gp130 in murine cardiac myocytes. Res Commun Mol Pathol Pharmacol1996; 93: 149–162.
61.
KunisadaKToneEFujioY. Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes. Circulation1998; 98: 346–352.
62.
LatchmanDS. Cardiotrophin-1: a novel cytokine and its effects in the heart and other tissues. Pharmacol Ther2000; 85: 29–37.
KunisadaKNegoroSToneE. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc Natl Acad Sci USA2000; 97: 315–319.
65.
TakahashiNSaitoYKuwaharaK. Hypertrophic responses to cardiotrophin-1 are not mediated by STAT3, but via a MEK5-ERK5 pathway in cultured cardiomyocytes. J Mol Cell Cardiol2005; 38: 185–192.
66.
McMullenJRShioiTZhangL. Phosphoinositide 3-kinase (p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA2003; 100: 12355–12360.
67.
DeBoschBTreskovILupuTS. Akt1 is required for physiological cardiac growth. Circulation2006; 113: 2097–2104.
68.
RakusanRMicrocirculation in the stressed heart. In: LegatoMJ (eds). The stressed heart, Boston, Dordrecht, and Lancaster: Martinus Nijhoff Publ, 1987, pp. 107–123.
69.
RakobowchukMHarrisETaylorA. Heavy and moderate interval exercise training alters low-flow-mediated constriction but does not increase circulating progenitor cells in healthy humans. Exp Physiol2012; 97: 375–385.
70.
LukTHDaiYLSiuCW. Effect of exercise training on vascular endothelial function in patients with stable coronary artery disease: a randomized controlled trial. Eur J Cardiovasc Prev Rehabil2012; 19: 830–839.
71.
FrenzelHSchwartzkopffBHöltermannW. Regression of cardiac hypertrophy: morphometric and biochemical studies in rat heart after swimming training. J Mol Cell Cardiol1988; 20: 737–751.
72.
Van CraenenbroeckEMHoymansVYBeckersPJ. Exercise training improves function of circulating angiogenic cells in patients with chronic heart failure. Basic Res Cardiol2010; 105: 665–676.
73.
NikolSKuhlmannM. Mobilization of stem cells in cardiovascular disease. Improvement of vascularization, cardiac function and arrhythmias. Med Klin (Munich)2006; 101: 190–192.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
